Patents by Inventor Alexander Berthold Hendrik Bakker
Alexander Berthold Hendrik Bakker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109966Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: ApplicationFiled: June 30, 2023Publication date: April 4, 2024Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko VAN LOO
-
Publication number: 20240058444Abstract: The present invention relates to a (bio)pharmaceutical composition, particularly a liquid (e.g. aqueous) biopharmaceutical composition, more particularly a liquid biopharmaceutical composition comprising an anti-EGFR/anti-LGR5 bispecific antibody. The present invention also relates inter alia to a method of manufacturing the composition, to a kit including the composition, to a package including the composition, to a method of manufacturing the package, and to methods of treatment using the composition and/or package, especially cancer treatments, for example, for the treatment of colorectal cancer.Type: ApplicationFiled: December 16, 2021Publication date: February 22, 2024Inventors: Alexander Berthold Hendrik BAKKER, Linda Johanna Aleida HENDRIKS, Robert Paul DOORNBOS, Tudor ARVINTE, Guillaume Desire DARPIN, Emilie Brigitte POIRIER
-
Patent number: 11873338Abstract: The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.Type: GrantFiled: December 20, 2019Date of Patent: January 16, 2024Assignee: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Cornelis Jacob Johannes George Bol, Pieter Fokko Van Loo, Leonardo Andres Sirulnik, Ernesto Isaac Wasserman
-
Patent number: 11739148Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: GrantFiled: January 11, 2019Date of Patent: August 29, 2023Assignee: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo
-
Publication number: 20230242669Abstract: Abstract: The invention relates among others to antibodies comprising a first antigen- binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B- 3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb R-2/3 positive tumor.Type: ApplicationFiled: October 19, 2022Publication date: August 3, 2023Applicant: Merus N.V.Inventors: Cecilia Anna Wilhelmina GEUIJEN, Cornelis Adriaan DE KRUIF, Mark THROSBY, Ton LOGTENBERG, Alexander Berthold Hendrik BAKKER
-
Publication number: 20220348683Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.Type: ApplicationFiled: February 18, 2022Publication date: November 3, 2022Applicant: Merus N.V.Inventors: Cecilia Anna Wilhelmina GEUIJEN, Cornelis Adriaan DE KRUIF, Mark THROSBY, Ton LOGTENBERG, Alexander Berthold Hendrik BAKKER
-
Publication number: 20220127375Abstract: The invention relates to means and methods of producing at least two antibodies. Methods may include providing cells with nucleic acid that encodes the antibodies; culturing said cells; collecting the antibodies from the culture; and separating produced antibodies from half antibodies by ion exchange chromatography (IEX). In some embodiments the antibodies exhibit IEX retention times that that deviate by 10% or less from the average of the retention times of the individual antibodies under the IEX conditions used. The invention also relates to compositions of antibodies thus produced. In some aspects the invention relates to compositions comprising 2-10 recombinant antibodies characterized in that the IEX retention times of at least two of said antibodies deviate by 10% or less from the average of the retention times of the individual antibodies under the IEX conditions.Type: ApplicationFiled: February 13, 2020Publication date: April 28, 2022Applicant: Merus N.V.Inventors: Robert Paul DOORNBOS, Alexander Berthold Hendrik BAKKER
-
Patent number: 11279770Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.Type: GrantFiled: February 27, 2015Date of Patent: March 22, 2022Assignee: Merus N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Cornelis Adriaan De Kruif, Mark Throsby, Ton Logtenberg, Alexander Berthold Hendrik Bakker
-
Publication number: 20220010013Abstract: The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.Type: ApplicationFiled: December 20, 2019Publication date: January 13, 2022Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik BAKKER, Comellis Jacob Johannes Georgr BOL, Pieter Fokko VAN LOO, Lenardo Andres SIRULNIK, Emesto Isaac WASSERMAN
-
Publication number: 20200384084Abstract: The invention relates to a method of activating a T cell in a subject and to a method of treating a cancer in a subject with a bispecific antibody and IL-15. The invention also relates to a pharmaceutical composition and to a kit comprising the bispecific antibody and IL-15. The invention further relates to a bispecific antibody for use in activating a T cell in a subject, to a bispecific antibody for use in the manufacture of a medicament for activating a T cell in a subject and to a product comprising a bispecific antibody and the mentioned IL-15.Type: ApplicationFiled: November 30, 2018Publication date: December 10, 2020Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko VAN LOO
-
Publication number: 20190352393Abstract: Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.Type: ApplicationFiled: April 19, 2019Publication date: November 21, 2019Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo, Ton Logtenberg
-
Patent number: 10358492Abstract: Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.Type: GrantFiled: September 27, 2013Date of Patent: July 23, 2019Assignee: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo, Ton Logtenberg
-
Publication number: 20190211100Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSs with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: ApplicationFiled: January 11, 2019Publication date: July 11, 2019Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko VAN LOO
-
Patent number: 10266593Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS CFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2 RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: GrantFiled: February 5, 2018Date of Patent: April 23, 2019Assignee: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo
-
Publication number: 20180237523Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS CFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2 RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: ApplicationFiled: February 5, 2018Publication date: August 23, 2018Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko Van Loo
-
Patent number: 9914777Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence (SEQ ID NO: 61): QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2 RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: GrantFiled: July 8, 2016Date of Patent: March 13, 2018Assignee: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo
-
Publication number: 20170037145Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.Type: ApplicationFiled: February 27, 2015Publication date: February 9, 2017Inventors: Cecilia Anna Wilhelmina GEUIJEN, Cornelis Adriaan DE KRUIF, Mark THROSBY, Ton LOGTENBERG, Alexander Berthold Hendrik BAKKER
-
Publication number: 20160368988Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: ApplicationFiled: July 8, 2016Publication date: December 22, 2016Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko VAN LOO
-
Patent number: 9005624Abstract: Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. In certain embodiments, they can be used in the post-exposure prophylaxis of rabies.Type: GrantFiled: April 8, 2010Date of Patent: April 14, 2015Assignee: Crucell Holland B.V.Inventors: Alexander Berthold Hendrik Bakker, Willem Egbert Marissen, Robert Arjen Kramer, Cornelis Adriaan De Kruif
-
Publication number: 20140120096Abstract: Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.Type: ApplicationFiled: September 27, 2013Publication date: May 1, 2014Applicant: MERUS B.V.Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko VAN LOO, Ton LOGTENBERG